- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00450216
Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. The study is designed to determine whether the combination product reduces the rate of ulcer development in subjects who require long-term daily use of ibuprofen.
Subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a 24 week treatment period or until they develop either an endoscopically-diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Subjects will visit the study center for Screening and at Weeks 4, 8, 16, and 24. Physical exams will be performed, and clinical laboratory measurements made, at selected times during the study. Endoscopic exams will be performed during Screening and at Weeks 8, 16, and 24. Subjects will be contacted four weeks following study completion.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Expected to require daily administration of an NSAID for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain.
- Did not use a NSAID within the 30 days prior to study entry
Exclusion Criteria:
- History of erosive esophagitis
History of any of the following serious gastrointestinal complications:
- perforation of ulcers,
- gastric outlet obstruction due to ulcers, or
- gastrointestinal bleeding.
- Active cardiac, renal, and/or hepatic disease
- Current Helicobacter pylori (H. pylori) infection
- Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin within the 14 days prior to study entry.
- Uncontrolled diabetes
- Uncontrolled hypertension
- Positive pregnancy test at screening
- Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- Currently participating, or participation within 30 days prior to study entry, in an investigational drug study
Please note that there are other additional criteria. The study center will determine if patients meet all of the criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
HZT-501: Ibuprofen 800mg/famotidine 26.6mg
|
HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
|
Active Comparator: 2
Ibuprofen 800mg
|
Ibuprofen 800mg administered orally 3 times daily for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers
Time Frame: 24 weeks
|
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment.
An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth.
A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.
Time Frame: 24 weeks
|
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment.
An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth.
A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
|
24 weeks
|
Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.
Time Frame: 24 weeks
|
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment.
An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth.
A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
|
24 weeks
|
The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)
Time Frame: 24 weeks
|
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment.
A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.
|
24 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Histamine Antagonists
- Histamine Agents
- Histamine H2 Antagonists
- Ibuprofen
- Famotidine
Other Study ID Numbers
- HZ-CA-303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
Groupe Hospitalier Paris Saint JosephCompletedUlcer, Leg | Ulcer AlgicFrance
-
Paul EdwardsCompletedDecubitis UlcerUnited States
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Assistance Publique - Hôpitaux de ParisRecruitingVenous Ulcer | Diabetic Ulcer | Sickle Cell Ulcer | Post-partum Women | Mixed UlcerFrance
-
AstraZenecaCompletedGastric Ulcer | Duodenal UlcerUnited States, Bulgaria, Czech Republic, Korea, Republic of, Russian Federation, South Africa, Philippines, Poland, Romania, Finland, Norway, Canada, Mexico, Argentina, Australia, Germany, Portugal, Slovakia, Thailand, Indonesia
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
Smith & Nephew, Inc.TerminatedSurgical Incision | Pressure Ulcer | Ulcer Foot | Wound Dehiscence | Ulcer, Leg | Ulcer VenousUnited Kingdom, Germany
-
Skilled Skin S.L.CompletedSurgical Wound | Diabetic Foot Ulcer | Skin Lesion | Pressure Ulcer | Hematoma | Venous Ulcer | Ischemic Ulcer | Arterial Ulcer | Diabetic Neuropathic Ulcer | Traumatic Ulcer | Ulcer, SkinSpain
Clinical Trials on Ibuprofen/famotidine
-
Horizon Pharma Ireland, Ltd., Dublin IrelandPediatric Rheumatology Collaborative Study GroupCompletedJuvenile Idiopathic ArthritisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Spain, Italy
-
Sherief Abd-ElsalamRecruiting
-
Istanbul Medeniyet UniversityCompleted
-
Ruttonjee HospitalCompletedPeptic Ulcer/ErosionsChina
-
Perrigo CompanyCompleted
-
Assistance Publique - Hôpitaux de ParisINSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders...Recruiting
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States